Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing

Foghorn Therapeutics Inc.

FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.
Preclinical combo data: FHD-909 synergistic with pembrolizumab and KRAS inhibitors, supporting clinical exploration.
Selective CBP degrader synergistic with paclitaxel and abemaciclib in ER+ breast cancer models.
Selective EP300 degrader shows preclinical activity in DLBCL and multiple myeloma; no thrombocytopenia.
ARID1B degrader program update expected in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.